Neratinib + Capecitabine in HER2+ Breast Cancer

Neratinib + Capecitabine in HER2+ Breast Cancer

Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2 Breast CancerПодробнее

Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2 Breast Cancer

Pyrotinib Plus Capecitabine for HER2 Metastatic Breast CancerПодробнее

Pyrotinib Plus Capecitabine for HER2 Metastatic Breast Cancer

HER2+ De Novo MBC: Neratinib Vs Lapatinib Plus CapecitabineПодробнее

HER2+ De Novo MBC: Neratinib Vs Lapatinib Plus Capecitabine

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma Mahtani

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment Approaches

Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trialsПодробнее

Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials

Dr. Nye on Neratinib-Associated Diarrhea in HER2+ Breast CancerПодробнее

Dr. Nye on Neratinib-Associated Diarrhea in HER2+ Breast Cancer

Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain MetastasesПодробнее

Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain Metastases

Brain Metastases in HER2-Positive Breast CancerПодробнее

Brain Metastases in HER2-Positive Breast Cancer

Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain MetastasesПодробнее

Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain Metastases

Dr. Freedman on Neratinib Plus Capecitabine for CNS Disease from HER2-Positive Breast CancerПодробнее

Dr. Freedman on Neratinib Plus Capecitabine for CNS Disease from HER2-Positive Breast Cancer